Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Corticosteroid Treatment for Hospitalized Patients With Severe Acute Respiratory Infection and Hypoxemia
NCT07199192Phase 4Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in severe acute respiratory infection (SARI) and hypoxemia (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: 28-day in-hospital mortality, Advanced respiratory support at 28 days and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Conditions
severe acute respiratory infection (SARI)hypoxemia
Beyond the preview
Go deeper on NCT07199192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199192.